Sir, An investigation of intraocular lens damage and foreign bodies using an injectable hydrophilic acrylic lens implant
We read with interest the report of the problems S Harsum et al 1 encountered with the hexagonal injecting system for the Raynor C-flex 570C. Our experience was identical. Initially, it was suggested that we were loading the lens incorrectly. Ultimately, we removed the foreign body fragments and sent these with the offending cartridges to the company for their analysis.
The change in design with the round tip to the nozzle appears to be successful, and we have not encountered any difficulties since.
Your study emphasises the importance of reporting difficulties with devices to the manufacturer and the MHRA.
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The authors declare no conflict of interest. A Pyott and C Barras Sir, Treatment of a choroidal neovascular membrane in a patient with late-onset retinal degeneration (L-ORD) with intravitreal Ranibizumab
We report the first case of a choroidal neovascular membrane (CNV) in a patient with late-onset retinal degeneration (L-ORD) successfully treated with intravitreal Ranibizumab (Lucentis).
Case report
A 61-year-old man, heterozygous for the Ser163Arg mutation in C1QTNF5, presented with a 4-week history of distortion in his right eye. His visual acuity (VA) was 68 ETDRS letters OD and 82 letters OS. Fundus fluorescein angiography (FFA) showed a juxtafoveal classic CNV (Figure 1 ) and optical coherence tomography (OCT) confirmed intra-retinal oedema over the area of the CNV (Figure 1 ). Owing to the reported poor outcome from the use of focal argon laser photocoagulation in such cases, 1 the patient received an intravitreal injection of Ranibizumab (0.5 mg). This was followed by two further injections at 4-weekly intervals. Four weeks after receiving the 
